NIH Tees Up Monkeypox Vaccine Trial to Test US Dose-Sparing Plan

A monkeypox clinical trial at the NIH will evaluate the US approach to increasing vaccine supply with smaller, more superficially administered doses, answering critical questions as cases climb.

The clinical trial will likely begin within the next month as the National Institute of Allergy and Infectious Diseases is in the late planning stages, Emily Erbelding, director of NIAID’s microbiology and infectious diseases division, said during a webinar hosted by the National Academy of Medicine and the American Public Health Association.

It’s one of several studies the National Institutes of Health is either undertaking or considering as cases have grown to ...